Bamco Inc Myovant Sciences Ltd. Transaction History

Bamco Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$5.19 - $9.46 $871,920 - $1.59 Million	-168,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.83 - $24.45 $471,239 - $684,600	28,000 Added 20.0%	168,000 $4.01 Million
Q4 2018 Feb 14, 2019	BUY	$15.01 - $25.2 $108,657 - $182,422	7,239 Added 5.45%	140,000 $2.3 Million
Q3 2018 Nov 14, 2018	BUY	$19.33 - $26.78 $1.44 Million - $2 Million	74,561 Added 128.11%	132,761 $3.53 Million
Q2 2018 Aug 14, 2018	BUY	$19.2 - $25.14 $1.12 Million - $1.46 Million	58,200 New	58,200 $1.33 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

Stay updated on Bamco Inc with notifications on news.